Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses.
Antibody response
COVID-19
Lung cancer
SARS-CoV-2
mRNA vaccine
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
11
08
2021
revised:
10
10
2021
accepted:
25
10
2021
pubmed:
20
11
2021
medline:
29
1
2022
entrez:
19
11
2021
Statut:
ppublish
Résumé
Coronavirus disease 2019 resulted in a 30% mortality rate in patients with thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine registration trials, it is still unknown whether they would develop a protective antispike antibody response after vaccination. This prospective vaccine monitoring study primarily aimed to assess humoral responses to the SARS-CoV-2 vaccine in patients with thoracic cancer. SARS-CoV-2-spike antibodies were measured using the Abbot Architect SARS-CoV-2 immunoglobulin G immunoassay before the first injection of BNT162b2 mRNA vaccine, at week 4, and 2 to 16 weeks after the second vaccine dose administration. The factors associated with antibody response were analyzed. Overall, 306 patients, with a median age of 67.0 years (interquartile range: 58-74), were vaccinated. Of these, 283 patients received two vaccine doses at 28-day intervals. After a 6.7-month median follow-up, eight patients (2.6%) contracted proven symptomatic SARS-CoV-2 infection, with rapid favorable evolution. Of the 269 serologic results available beyond day 14 after the second vaccine dose administration, 17 patients (6.3%) were still negative (<50 arbitrary units/mL, whereas 34 (11%) were less than 300 arbitrary units/mL (12.5th percentile). In multivariate analysis, only age (p < 0.01) and long-term corticosteroid treatment (p = 0.01) were significantly associated with a lack of immunization. A total of 30 patients received a third vaccine dose, with only three patients showing persistently negative serology thereafter, whereas the others exhibited clear seroconversion. SARS-CoV2 vaccines were found to be efficient in patients with thoracic cancer, most of them being immunized after two doses. A third shot given to 1% of patients with persistent low antibody titers resulted in an 88% immunization rate.
Identifiants
pubmed: 34798306
pii: S1556-0864(21)03286-X
doi: 10.1016/j.jtho.2021.10.015
pmc: PMC8593625
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
RNA, Viral
0
Vaccines, Synthetic
0
mRNA Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
239-251Informations de copyright
Copyright © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Références
Eur J Cancer. 2020 Dec;141:62-81
pubmed: 33129039
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
Ann Oncol. 2020 Oct;31(10):1386-1396
pubmed: 32561401
JAMA Oncol. 2021 Aug 1;7(8):1133-1140
pubmed: 34047765
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Euro Surveill. 2017 Jul 27;22(30):
pubmed: 28797322
Lancet. 2021 May 1;397(10285):1646-1657
pubmed: 33901420
J Infect Dis. 2021 May 28;223(10):1666-1670
pubmed: 33580259
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Cancer Cell. 2020 Jun 8;37(6):742-745
pubmed: 32425702
N Engl J Med. 2021 Mar 4;384(9):e28
pubmed: 33596347
Nat Med. 2021 Aug;27(8):1367-1369
pubmed: 34113015
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
Nature. 2021 Aug;596(7872):417-422
pubmed: 34192737
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
J Immunother Cancer. 2021 May;9(5):
pubmed: 34016723
Lancet. 2021 Mar 6;397(10277):879-880
pubmed: 33617766
Public Health. 2020 Dec;189:129-134
pubmed: 33227595
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Euro Surveill. 2021 Jul;26(28):
pubmed: 34269174
Oncologist. 2012;17(3):436-45
pubmed: 22357731
Ann Oncol. 2021 Aug;32(8):1053-1055
pubmed: 33932508
Lancet Respir Med. 2021 Nov;9(11):e104-e105
pubmed: 34687656
Clin Exp Med. 2021 Jul 20;:
pubmed: 34283338
Lancet Oncol. 2020 Jul;21(7):904-913
pubmed: 32479787
Lancet Oncol. 2021 May;22(5):581-583
pubmed: 33812495
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Int J Infect Dis. 2020 Dec;101:138-148
pubmed: 33007452
Int J Infect Dis. 2020 Aug;97:1-6
pubmed: 32339723
Science. 2021 Jul 9;373(6551):
pubmed: 34035154
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2021 Feb 18;384(7):643-649
pubmed: 33378605
Eur J Epidemiol. 2020 Dec;35(12):1123-1138
pubmed: 33289900
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
J Infect Dis. 2012 Oct;206(8):1250-9
pubmed: 22904335
Ann Oncol. 2021 Aug;32(8):1051-1053
pubmed: 33932501
Lancet Haematol. 2021 Aug;8(8):e542-e544
pubmed: 34224667
J Geriatr Oncol. 2021 Nov;12(8):1253-1255
pubmed: 34175246
Cancer Cell. 2021 Aug 9;39(8):1028-1030
pubmed: 34242572
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155
Eur J Cancer. 2021 Aug;153:260-264
pubmed: 34183225